Literature DB >> 15893407

Synergistic inhibition of respiration in brain mitochondria by nitric oxide and dihydroxyphenylacetic acid (DOPAC). Implications for Parkinson's disease.

Carla Nunes1, Leonor Almeida, João Laranjinha.   

Abstract

The inhibition of mitochondrial respiration by nitric oxide (.NO) at cytochrome c oxidase level has been established as a physiological regulatory mechanism of mitochondrial function. Given, on the one hand, the potential involvement of .NO and dopamine metabolism in mitochondrial dysfunction associated with neurodegeneration and, on the other hand, the reported interaction of .NO with dihydroxyphenylacetic acid (DOPAC), a major mitochondrial-associated dopamine metabolite, we examined the combined effects of .NO and DOPAC on the respiratory chain of isolated rat brain mitochondria. Whereas dopamine or DOPAC induced no measurable effects on the mitochondrial respiration rate, a mixture of .NO with DOPAC inhibited the rate in a way stronger than that exerted by .NO. This effect was noticed with actively respiring (state 3) and resting (state 4) mitochondria. At variance with DOPAC, dopamine failed to potentiate .NO inhibitory effects. The inhibition was dependent on the concentration of both compounds, .NO and DOPAC, and exhibited characteristics similar to those exerted by .NO, namely: it was reversible and dependent on the concentration of oxygen. Analysis of respiratory enzymatic activities demonstrated a selective inhibition at the level of cytochrome c oxidase (complex IV). Insights into the chemical mechanisms underlying the inhibitory effect were inferred from experiments using metmyoglobin (a ligand for .NO and derived species, such as nitroxyl anion) and ferrocyanide (a reductant of .NO, producing nitroxyl anion). Whereas metmyoglobin decreased the inhibition, ferrocyanide potentiated the inhibition. Moreover, a mixture of ferrocyanide with .NO reproduced the effects exerted by the mixture of .NO with DOPAC. The results are consistent with the notion of a reaction of .NO with DOPAC producing a nitric oxide-derived compound(s), which inhibit O2 uptake at the cytochrome oxidase level. Although the mechanism in question remains to be clearly elucidated it is suggested that the .NO/DOPAC-dependent inhibition of cytochrome oxidase may involve nitroxyl anion. The significance of these observations for mitochondrial dysfunction inherent in Parkinson's disease is discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15893407     DOI: 10.1016/j.neuint.2005.03.005

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  6 in total

Review 1.  The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the Janus face of NO.

Authors:  Nazareno Paolocci; Matthew I Jackson; Brenda E Lopez; Katrina Miranda; Carlo G Tocchetti; David A Wink; Adrian J Hobbs; Jon M Fukuto
Journal:  Pharmacol Ther       Date:  2006-11-29       Impact factor: 12.310

2.  The Peculiar Facets of Nitric Oxide as a Cellular Messenger: From Disease-Associated Signaling to the Regulation of Brain Bioenergetics and Neurovascular Coupling.

Authors:  João Laranjinha; Carla Nunes; Ana Ledo; Cátia Lourenço; Bárbara Rocha; Rui M Barbosa
Journal:  Neurochem Res       Date:  2020-03-19       Impact factor: 3.996

Review 3.  The Interactions between Polyphenols and Microorganisms, Especially Gut Microbiota.

Authors:  Małgorzata Makarewicz; Iwona Drożdż; Tomasz Tarko; Aleksandra Duda-Chodak
Journal:  Antioxidants (Basel)       Date:  2021-01-28

Review 4.  Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota: a review.

Authors:  Aleksandra Duda-Chodak; Tomasz Tarko; Paweł Satora; Paweł Sroka
Journal:  Eur J Nutr       Date:  2015-02-12       Impact factor: 5.614

Review 5.  Nitrosative stress in Parkinson's disease.

Authors:  Morgan G Stykel; Scott D Ryan
Journal:  NPJ Parkinsons Dis       Date:  2022-08-11

6.  Serum insulin-like growth factor-1 and nitric oxide levels in Parkinson's disease.

Authors:  Deniz Tuncel; Fatma Inanc Tolun; Ismail Toru
Journal:  Mediators Inflamm       Date:  2009-03-12       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.